Brief: Adagene Announces Poster Presentations On Anti-CTLA-4 NEObody, ADG116, At Upcoming SITC Annual Meeting In November
11/10/2022 21:24
Oct 11 (Reuters) - Adagene Inc 978y.F :
* ADAGENE ANNOUNCES POSTER PRESENTATIONS ON ANTI-CTLA-4
NEOBODY™,
ADG116, AT UPCOMING SOCIETY FOR IMMUNOTHERAPY OF CANCER’S (SITC)
ANNUAL MEETING IN NOVEMBER
Source text for Eikon: ID:nGNX10yptX
Further company coverage: 978y.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adagene
See all newsBrief: Adagene To Begin Phase 1 Study Of ADG138 For Advanced Solid Tumors In Q4 2026
Brief: Adagene Announces That Third Arc Bio Has Selected First Lead Candidate Under Amended Strategic Collaboration For Development Of Masked Cd3 T Cell Engagers Utilizing Safebody® Technology
Brief: Adagene Inc Announces Offering Of American Depositary Shares
Brief: Adagene Announces FDA Fast Track Designation For Muzastotug (Adg126)
Brief: Adagene Expands SAFEBody Deal With Exelixis To Develop Third Novel Masked Antibody-Drug Conjugate